{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:36:26Z","timestamp":1774416986851,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jpba.2022.114693","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T11:09:55Z","timestamp":1645873795000},"page":"114693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies"],"prefix":"10.1016","volume":"214","author":[{"given":"Tuba","family":"Re\u00e7ber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selin Seda","family":"Timur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevilay","family":"Erdo\u011fan Kablan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tutku Ceren","family":"Karabulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Neslihan G\u00fcrsoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Ero\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedef","family":"K\u0131r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emirhan","family":"Nemutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2022.114693_bib1","unstructured":"2022. \u3008https:\/\/covid19.who.int\/measures\u3009. (Accessed 10 Jaunary 2022)."},{"key":"10.1016\/j.jpba.2022.114693_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2021.06.003","article-title":"Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19","author":"Painter","year":"2021","journal-title":"Curr. Opin. Virol."},{"issue":"515","key":"10.1016\/j.jpba.2022.114693_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.jpba.2022.114693_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","volume":"297","author":"Gordon","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.jpba.2022.114693_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2022.114693_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122150","article-title":"Development of a RP-HPLC method for simultaneous determination of reference markers used for in-situ rat intestinal permeability studies","volume":"1147","author":"Soyseven","year":"2020","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2022.114693_bib7","unstructured":"EMA, ICH M9 Guideline on Biopharmaceutics Classification System-based Biowaivers, in: C.f.M.P.f.H. Use (Ed.),\u00a02020."},{"key":"10.1016\/j.jpba.2022.114693_bib8","unstructured":"FDA, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, in: U.S.D.o.H.a.H.S.F.a.D.A.C.f.D.E.a.R. (CDER) (Ed.), 2017."},{"issue":"3","key":"10.1016\/j.jpba.2022.114693_bib9","first-page":"235","article-title":"In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives","volume":"45","author":"Buckley","year":"2012","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"issue":"1\u20133","key":"10.1016\/j.jpba.2022.114693_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(00)00128-9","article-title":"Caco-2 monolayers in experimental and theoretical predictions of drug transport","volume":"46","author":"Artursson","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jpba.2022.114693_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10565-005-0085-6","article-title":"The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics","volume":"21","author":"Sambuy","year":"2005","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.jpba.2022.114693_bib12","unstructured":"O. McPolin, An introduction to HPLC for pharmaceutical analysis, Lulu.com, Mourine Training Services, Northern, Ireland, UK, 2009."},{"key":"10.1016\/j.jpba.2022.114693_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114356","article-title":"The development and validation of a novel LC-MS\/MS method for the simultaneous quantification of Molnupiravir and its metabolite \u00df-d-N4-hydroxycytidine in human plasma and saliva","volume":"206","author":"Amara","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.114693_bib14","unstructured":"I.H.T. Guideline, Validation of Analytical Procedures: Text and Methodology, Q2 (R1) 1(20) (2005), 5."},{"key":"10.1016\/j.jpba.2022.114693_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejpb.2019.01.017","article-title":"Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer","volume":"136","author":"Timur","year":"2019","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arb. Pharm. Verfahr."},{"issue":"3","key":"10.1016\/j.jpba.2022.114693_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biopha.2004.02.001","article-title":"Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs","volume":"58","author":"Gursoy","year":"2004","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"key":"10.1016\/j.jpba.2022.114693_bib17","unstructured":"ICH Harmonised Tripartite Guideline, Validationof analytical procedures: text and methodology, Q2 (R1) 1(20) (2005), 5."},{"issue":"5","key":"10.1016\/j.jpba.2022.114693_bib18","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1021\/mp500152y","article-title":"The low\/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol","volume":"11","author":"Zur","year":"2014","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.jpba.2022.114693_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2478\/acph-2020-0006","article-title":"Biopharmaceutical classification of desloratadine - not all drugs are classified the easy way","volume":"70","author":"Berginc","year":"2020","journal-title":"Acta Pharm."},{"issue":"6","key":"10.1016\/j.jpba.2022.114693_bib20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1021\/mp060042f","article-title":"The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests","volume":"3","author":"Kim","year":"2006","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.jpba.2022.114693_bib21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1021\/mp300410n","article-title":"Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification","volume":"10","author":"Incecayir","year":"2013","journal-title":"Mol. Pharm."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522001145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522001145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:17:57Z","timestamp":1760001477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522001145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":21,"alternative-id":["S0731708522001145"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114693","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114693"}}